Colchicine failure in familial mediterranean fever and potential alternatives: Embarking on the Anakinra trial

Israel Medical Association Journal

Volumn 16, Issue 5, 2014, Pages 271-273

  Ben Zvi, Ilan ^a,b,c   Livneh, Avi ^a,c  

^a HELLER INSTITUTE OF MEDICAL RESEARCH   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Anakinra; Colchicine; Familial Mediterranean fever (FMF); Inflammasome; Interleukin 1 (IL 1 )

Indexed keywords

CANAKINUMAB; COLCHICINE; INFLAMMASOME; INTERLEUKIN 1BETA; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

AMYLOIDOSIS; ANEMIA; ARTICLE; FAMILIAL MEDITERRANEAN FEVER; GROWTH RETARDATION; HUMAN; INJECTION SITE REACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; ANTIRHEUMATIC AGENTS; CLINICAL PROTOCOLS; COLCHICINE; CYTOSKELETAL PROTEINS; DOUBLE-BLIND METHOD; DRUG RESISTANCE; FAMILIAL MEDITERRANEAN FEVER; FEMALE; HUMANS; INFLAMMASOMES; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; ISRAEL; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84901679747     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Ben-Chetrit E, Touitou I. Familial mediterranean fever in the world. Arthritis Rheum 2009; 61: 1447-53.
2. Ben-Zvi I, Livneh A. Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nat Rev Rheumatol 2010; 7: 105-12.
3. Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 1986; 314: 1001-5.
4. Zemer D, Revach M, Pras M, et al. A controlled trial of colchicine in preventing attacks of familial mediterranean fever. N Engl J Med 1974; 291: 932-4.
5. Cerquaglia C, Diaco M, Nucera G, La Regina M, Montalto M, Manna R. Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update. Curr Drug Targets Inflamm Allergy 2005; 4: 117-24.
6. Lidar M, Scherrmann JM, Shinar Y, et al. Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum 2004; 33: 273-82.
7. Hentgen V, Grateau G, Kone-Paut I, et al. Evidence-based recommendations for the practical management of Familial Mediterranean Fever. Semin Arthritis Rheum 2013; 43: 387-91.
8. La Regina M, Ben-Chetrit E, Gasparyan AY, Livneh A, Ozdogan H, Manna R. Current trends in colchicine treatment in familial Mediterranean fever. Clin Exp Rheumatol 2013; 31: 41-6.
9. Lidar M, Kedem R, Langevitz P, Pras M, Livneh A. Intravenous colchicine for treatment of patients with familial Mediterranean fever unresponsive to oral colchicine. J Rheumatol 2003; 30: 2620-3.
10. Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol 2013; 25 (6): 469-84.
11. Hashkes PJ, Spalding SJ, Giannini EH, et al. Rilonacept for colchicine-resistant or-intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med 2012; 157: 533-41.
12. Hacihamdioglu DO, Ozen S. Canakinumab induces remission in a patient with resistant familial Mediterranean fever. Rheumatology (Oxford) 2012; 51: 1041.
13. Mitroulis I, Skendros P, Oikonomou A, Tzioufas AG, Ritis K. The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis. Ann Rheum Dis 2011; 70: 1347-8.
14. Calligaris L, Marchetti F, Tommasini A, Ventura A. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr 2008; 167: 695-6.
15. Gattringer R, Lagler H, Gattringer KB, et al. Anakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever: effective but risky. Eur J Clin Invest 2007; 37: 912-14.
16. Kuijk LM, Govers AM, Frenkel J, Hofhuis WJ. Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann Rheum Dis 2007; 66: 1545-6.
17. Mitroulis I, Papadopoulos VP, Konstantinidis T, Ritis K. Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient. Neth J Med 2008; 66: 489-91.
18. Ozen S, Bilginer Y, Aktay Ayaz N, Calguneri M. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol 2011; 38: 516-18.
19. Bilginer Y, Ayaz NA, Ozen S. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behcet's disease. Clin Rheumatol 2010; 29: 209-10.
20. Stankovic Stojanovic K, Delmas Y, Torres PU, et al. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol Dial Transplant 2012; 27: 1898-901.
21. Fujikawa K, Migita K, Tsukada T, et al. Interleukin-6 targeting therapy in familial Mediterranean fever. Clin Exp Rheumatol 2013; 31: 150-1.
22. Bagci S, Toy B, Tuzun A, et al. Continuity of cytokine activation in patients with familial Mediterranean fever. Clin Rheumatol 2004; 23: 333-7.
23. Bilgen SA, Kilic L, Akdogan A, et al. Effects of anti-tumor necrosis factor agents for familial Mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment. J Clin Rheumatol 2011; 17: 358-62.
24. Mor A, Pillinger MH, Kishimoto M, Abeles AM, Livneh A. Familial Mediterranean fever successfully treated with etanercept. J Clin Rheumatol 2007; 13: 38-40.
25. Ozgocmen S, Akgul O. Anti-TNF agents in familial Mediterranean fever: report of three cases and review of the literature. Mod Rheumatol 2011; 21: 684-90.
26. Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997; 40: 1879-85.